Results 1 to 10 of about 205,975 (308)

A Decade in Review: A Systematic Review of Universal Influenza Vaccines in Clinical Trials during the 2010 Decade

Viruses, 2020
On average, there are 3–5 million severe cases of influenza virus infections globally each year. Seasonal influenza vaccines provide limited protection against divergent influenza strains.
Brigette N. Corder, Brianna L. Bullard, Gregory A. Poland, Eric A. Weaver   +3 more
doaj   +1 more source

Impact of the coronavirus disease 2019 epidemic and a free influenza vaccine strategy on the willingness of residents to receive influenza vaccines in Shanghai, China

Human Vaccines & Immunotherapeutics, 2021
The influenza vaccine is not included in China’s national immunization program. Here, we assessed influenza vaccine coverage among Shanghai residents and estimated the impacts of the coronavirus disease 2019 (COVID-19) epidemic and a hypothetical free ...
Yehong Zhou, Jing Tang, Junjie Zhang, Qiangsong Wu   +3 more
doaj   +1 more source

N-glycosylation at the receptor binding site drives differences in receptor binding specificity between influenza B virus lineages

Journal of Virology
Receptor specificity plays a critical role in influenza virus host tropism and pathogenesis. Influenza A and influenza B viruses (FLUAVs and FLUBVs, respectively) utilize N-glycans with terminal sialic acids on glycoproteins decorating the surface of ...
Caroline K. Page, M. H. M. Mubassir, Pradeep Chopra, Lindsey Claire Gay, Ginger Geiger, Sean D. Ray, Justin D. Shepard, Rose J. Miller, Daniel Perez, Justin Bahl, Gerardus Josephus Boons, Stephen Mark Tompkins   +11 more
doaj   +1 more source

Incidence of viral respiratory infections in a prospective cohort of outpatient and hospitalized children aged ≤5 years and its associated cost in Buenos Aires, Argentina [PDF]

, 2015
Background: Although information about the incidence of viral respiratory illnesses and their associated cost can help health officials explore the value of interventions, data are limited from middle-income countries.
Azziz Baumgartner, Eduardo, Carballal, Guadalupe, Durand, Lizette O., Echavarría, Marcela Silvia, Ekstrom, Jorge, Marcone, Débora Natalia, Vidaurreta, Santiago Manuel   +6 more
core   +1 more source

Aged AG129 mice support the generation of highly virulent novel mouse-adapted DENV (1-4) viruses exhibiting neuropathogenesis and high lethality

Virus Research
Dengue virus infection in humans ranges from asymptomatic infection to severe infection, with ∼2.5 % overall disease fatality rate. Evidence of neurological manifestations is seen in the severe form of the disease, which might be due to the direct ...
Gazala Siddqui, Preeti Vishwakarma, Shikha Saxena, Varun Kumar, Sneh Bajpai, Amit Kumar, Satish Kumar, Ritika Khatri, Jaskaran Kaur, Sankar Bhattacharya, Shubbir Ahmed, Gulam Hussain Syed, Yashwant Kumar, Sweety Samal   +13 more
doaj   +1 more source

Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age [PDF]

, 2014
Background: Vaccines against pandemic A/H1N1 influenza should provide protective immunity in children, because they are at greater risk of disease than adults.
Abarca, Katia, Arora, Ashwani, Della Cioppa, Giovanni, Kieninger-Baum, Dorothee, Knuf, Markus, Lattanzi, Maria, Leroux-Roels, Geert, Pedotti, Paola, Rivera, Luis, Rümke, Hans C   +9 more
core   +2 more sources

The rise of companies from emerging markets in global health governance: opportunities and challenges [PDF]

, 2014
The article analyses the involvement of pharmaceutical companies from emerging markets in global health governance. It finds that they play a central role as low-cost suppliers of medicines and vaccines and, increasingly, new technologies.
ANNE ROEMER-MAHLER, Brooks, Brown, Buse, Chaudhuri, Clarke, Cooper Ramo, Drezner, Elbe, Fleury, Gold, Knight, Levy, Meyer, Petryna, Ramamurti, Roemer-Mahler, Schoofs, Wells, Whyte, Williams, Williamson, Youde, Zimmerman   +23 more
core   +1 more source

A review of the changes to the licensing of influenza vaccines in Europe [PDF]

, 2015
In 2014, the European Committee for Medicinal Products for Human Use (CHMP) published a draft regulatory guideline for the evaluation of influenza vaccines.
Voordouw, A.C.G. (Bettie), Wijnans, E.G. (Leonoor)   +1 more
core   +2 more sources

Advances in Nucleic Acid Universal Influenza Vaccines

Vaccines
Currently, vaccination with influenza vaccines is still an effective strategy to prevent infection by seasonal influenza virus in spite of some drawbacks with them.
Liang Xu, Weigang Ren, Qin Wang, Junwei Li   +3 more
doaj   +1 more source

Development of cross-protective influenza A vaccines based on cellular responses

Frontiers in Immunology, 2015
Seasonal influenza vaccines provide protection against matching influenza A virus (IAV) strains mainly through the induction of neutralizing serum IgG antibodies. However, these antibodies fail to confer a protective effect against mismatched IAV.
Peter Christiaan Soema, Peter Christiaan Soema, Elly evan Riet, Gideon eKersten, Gideon eKersten, Jean-Pierre eAmorij   +5 more
doaj   +1 more source